Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Jianmin Zhang, [email protected] These authors have contributed equally to this work This article was submitted to Neuro-Oncology and Neurosurgical Oncology, a section of the journal Frontiers in Oncology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
This three-part series from BioWorld highlights the strengths and weaknesses of major players in Chinas obesity and diabetes market, including the pressing line of Chinese semaglutide biosimilars, and a peek into the next potential blockbuster market for GLP-1s
How do GLP-1 medications improve blood sugar levels in people without diabetes
Free radicals are bad for the body, and this is its main job: to fight them
US$ 20.23
US$ 22.29
US$ 25.63
US$ 22.79
